PF-Atlas › Clinical Trials › NCT03830125

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

BBT-877, Single dose · Phase 1

Registry ID
NCT03830125
Phase
Phase 1
Status
Completed
Drug / intervention
BBT-877, Single dose
Sponsor
Bridge Biotherapeutics, Inc.
Start
2019-02-13
Enrollment
88
Locations
1

About this trial

This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.

View NCT03830125 on ClinicalTrials.gov →

Explore related

All BBT-877, Single dose trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03830125 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.